DLC-1 expression levels in breast cancer assessed by qRT-PCR are negatively associated with malignancy

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 4, 2012, Pages 1231-1233

  Guan, Cheng Nong ^a   Zhang, Pei Wen ^a   Lou, Hai Qing ^a   Liao, Xiang Hui ^a   Chen, Bao Ying ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

BREAST carcinoma; DLC 1; Malignancy; Negative correlation; QRT PCR

Indexed keywords

DLC1 PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; MESSENGER RNA; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BREAST; BREAST DISEASE; BREAST TUMOR; CANCER INVASION; CARCINOMA; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; METASTASIS; NONPARAMETRIC TEST; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

BREAST; BREAST DISEASES; BREAST NEOPLASMS; CARCINOMA; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; GTPASE-ACTIVATING PROTEINS; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84873032802     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.4.1231     Document Type: Article

References (21)

1. Durkin ME (2002). Gene structure, tissue expression and linkage mapping of the mouse DLC-1 gene (Arhgap7). Gene, 17, 119-23.
2. Guan M, Zhou X, Soulitzis N, Spandidos DA, Popescu NC (2006). Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin Cancer Res, 12, 1412-9.
3. Kim TY, Jong HS, Song SH, et al. (2003). Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Oncogene, 22, 3943-51.
4. Kim TY, Lee JW, Kim HP, et al. (2007). DLC-1, a GTPaseactivating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma. Biochem Biophys Res Commun, 355, 72-7.
5. Liu JB, Zhang SQ, Shi MX, Cai J (2008). Clinical value of the expression of the DLC-1 in hepatocellular carcinoma. J Modern Lab Med, 23, 76-8.
6. Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D (2004). Part I: Vaccines for solid tumours. Lancet Oncol, 5, 681-9.
7. Park SW, Durkin ME, Thorgeirsson SS, Popescu NC (2003). DNA variants of DLC-1, a candidate tumor suppressor gene, in human hepatocellular carcinoma. Int J Oncol, 23, 133-7.
8. Plaumann M, Seitz S, Frege R, Estevez-Schwarz L, Scherneck S (2003). Analysis of DLC-1 expression in human breast cancer. Cancer Res Clin Oncol, 129, 349-54.
9. Qian X, Li G, Asmussen HK, et a1. (2007). Oncogenic inhibition by adeleted in liver cancer gene requires cooperation between tensinbinding and Rho-specific GTPase-activating protein activities. Proc Natl Acad Sci USA, 104, 9012-7.
10. Sacha JH, Elizabeth A (2008). Prolactin receptor antagonism reduces theclonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity. Breast Cancer Res, 10, R68.
11. Sekimata M, Kabuyama Y, Emori Y, Homma Y (1999). Morphological changes and detachment of adherent cells induced by p122, a GTPase-activating protein for Rho. J Biol Chem, 274, 17757-62.
12. Seng TJ, Low JS, Li H, et al. (2007). The major 8p22 tumor suppressorDLC1 is frequently silenced by methylation in both endemic andsporadic nasopharyngeal, esophageal, and cervical carcinomas, andinhibits tumor cell colony formation. Oncogene, 26, 934-44.
13. Shang YF, Jin YL, Xu JJ, Li N, Huang PL (2008). Effect of DLC-1 gene on invasion and migration of human colorectal cancer cell line. Progress Modern Biomed, 8, 19-21.
14. Wong CM, Ee JM, Ching YP, et al. (2003). Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res, 63, 7646-51.
15. Wong CM, Yam JW, Ching YP, et al. (2005). Rho GTPaseactivating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res, 65, 8861-8.
16. Yam JW, Ko FC, Chan CY, Jin DY, Ng IO (2006). Interaction of deleted in liver cancer 1 with tensin in caveolaeand implications in tumor suppression. Cancer Res, 66, 8367-72.
17. Yin HL, Janmey PA (2003). Phosphoinositide regulation of the actin cytoskeleton. Annu Rev Physiol, 65, 761-89.
18. Yuan BZ, Zhou X, Durkin ME, et al. (2003). DLC-1gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene, 23, 445-50.
19. Yuan BZ, Jefferson AM, Baldwin TK, et a1. (2004). DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene, 237, 1405-11.
20. Yuan BZ, Burkin ME (2003). Promoter hypermethylation of DLC-1, candidate tumor suppressor gene, n several common human cancers. Cancer Genet Cytogenet, 15, 113-7.
21. Zhou X, Thorgeirsson SS, Popescu NC (2004). Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene, 23, 1308-13.